166 related articles for article (PubMed ID: 35835028)
21. Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience.
Sellner J; Sitte HH; Rommer PS
Drug Discov Today; 2021 Jul; 26(7):1591-1601. PubMed ID: 33781948
[TBL] [Abstract][Full Text] [Related]
22. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
Wallach AI; Tremblay M; Kister I
Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
[TBL] [Abstract][Full Text] [Related]
23. Blockade of IL-6 signaling in neuromyelitis optica.
Araki M
Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
[TBL] [Abstract][Full Text] [Related]
24. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
Valencia-Sanchez C; Wingerchuk DM
BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
[TBL] [Abstract][Full Text] [Related]
25. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders.
Duchow A; Paul F; Bellmann-Strobl J
Expert Opin Biol Ther; 2020 Sep; 20(9):1061-1072. PubMed ID: 32228250
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety of satralizumab in neuromyelitis optica spectrum disorder (NMOSD) from SAkuraSky and SAkuraStar.
Yamamura T; Weinshenker B; Yeaman MR; De Seze J; Patti F; Lobo P; von Büdingen HC; Kou X; Weber K; Greenberg B
Mult Scler Relat Disord; 2022 Oct; 66():104025. PubMed ID: 36007339
[TBL] [Abstract][Full Text] [Related]
27. Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.
Lotan I; McGowan R; Levy M
Curr Neuropharmacol; 2021; 19(2):220-232. PubMed ID: 32348222
[TBL] [Abstract][Full Text] [Related]
28. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
Romeo AR
Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
[TBL] [Abstract][Full Text] [Related]
29. [Neuromyelitis Optica Spectrum Disorder].
Misu T
Brain Nerve; 2021 May; 73(5):475-482. PubMed ID: 34006678
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
[TBL] [Abstract][Full Text] [Related]
32. New BBB Model Reveals That IL-6 Blockade Suppressed the BBB Disorder, Preventing Onset of NMOSD.
Takeshita Y; Fujikawa S; Serizawa K; Fujisawa M; Matsuo K; Nemoto J; Shimizu F; Sano Y; Tomizawa-Shinohara H; Miyake S; Ransohoff RM; Kanda T
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34667128
[TBL] [Abstract][Full Text] [Related]
33. A safe change from eculizumab to satralizumab in a patient with neuromyelitis optica spectrum disorder.
Funakoshi K; Suzuki K
Neurol Sci; 2023 Mar; 44(3):1097-1098. PubMed ID: 36350454
[No Abstract] [Full Text] [Related]
34. Neuromyelitis optica spectrum disorder safely and successfully treated with satralizumab during pregnancy and breastfeeding: a case report.
Yoshida T; Watanabe O; Nomura M; Yoshimoto Y; Maki Y; Takashima H
Front Neurol; 2023; 14():1322412. PubMed ID: 38162440
[TBL] [Abstract][Full Text] [Related]
35. Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder.
Matsuoka T; Araki M; Lin Y; Okamoto T; Gold R; Chihara N; Sato W; Kimura A; Tachimori H; Miyamoto K; Kusunoki S; Yamamura T
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37863660
[TBL] [Abstract][Full Text] [Related]
36. Cases of aquaporin-4-positive neuromyelitis optica spectrum disorder with successful tapering of prednisolone to less than 3 mg/day after satralizumab administration.
Nakamagoe K; Tanaka M; Igari K
Neurol Sci; 2023 Aug; 44(8):2967-2970. PubMed ID: 36933100
[No Abstract] [Full Text] [Related]
37. Satralizumab as a treatment for pediatric-onset neuromyelitis optica spectrum disorder with cluster attack: a case report.
Wang R; Sun D; Du Q; Shi Z; Chen H; Zhou H
J Neurol; 2023 Oct; 270(10):5085-5089. PubMed ID: 37204456
[No Abstract] [Full Text] [Related]
38. Long-term safety of satralizumab in NMOSD.
Lemprière S
Nat Rev Neurol; 2022 Sep; 18(9):510. PubMed ID: 35941197
[No Abstract] [Full Text] [Related]
39. New therapies for neuromyelitis optica spectrum disorder.
Levy M; Fujihara K; Palace J
Lancet Neurol; 2021 Jan; 20(1):60-67. PubMed ID: 33186537
[TBL] [Abstract][Full Text] [Related]
40. Emerging drugs for the treatment of neuromyelitis optica.
Duchow A; Chien C; Paul F; Bellmann-Strobl J
Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
